Kazuma Sugimoto

University of Tokyo Hospital

Japan

Research Interests

Explore related searches

Professors in Japan

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (7)

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Collaborators (6)

Tomoyuki Kaneko

Teikyo University

JAPAN

View details

Sebastiano Buti

ITALY

View details

Yukari Uemura

Section Chief

National Center For Global Health and Medicine

JAPAN

View details

Taketo Kawai

Teikyo University School of Medicine

JAPAN

View details

Kazuo Nishimura

Osaka International Cancer Institute

JAPAN

View details

Melissa Bersanelli

Adjunct Professor in Medical Oncology

University of Parma

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Kazuma Sugimoto

Research Interests

Explore related searches

Contact this professor

Articles (7)

Development of risk-score model in patients with negative surgical margin after robot-assisted radical prostatectomy.

Validation of a drug-based score in advanced urothelial carcinoma treated with pembrolizumab

Enfortumab vedotin versus platinum rechallenge in post-platinum, post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched study.

Paralytic Ileus during Treatment of Pulmonary and Renal Tuberculosis in a Non-Human Immunodeficiency Virus Patient: An Unusual Presentation of Tuberculosis-immune Reconstitution Inflammatory Syndrome.

Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma.

Improved survival in real-world patients with advanced urothelial carcinoma: A multicenter propensity score-matched cohort study comparing a period before the introduction of pembrolizumab (2003-2011) and a more recent period (2016-2020).

Hospital volume and postoperative survival for three urological cancers: Prostate, kidney, and bladder.

Collaborators (6)

Tomoyuki Kaneko

Sebastiano Buti

Yukari Uemura

Taketo Kawai

Kazuo Nishimura

Melissa Bersanelli

Make your next move.